MergerMay 4, 2026, 07:02 AM
Apimeds US Completes Merger, Approves Reverse Stock Split & Equity Plans
AI Summary
Apimeds Pharmaceuticals US, Inc. completed a merger with MindWave Innovations Inc. and Lokahi Therapeutics, Inc. on December 1, 2025, making MindWave a wholly-owned subsidiary. As a result, MindWave's former shareholders will hold 90.9% of Apimeds US's equity on an as-converted basis. Concurrently, shareholders approved a 1-for-10 reverse stock split and new equity incentive plans. The company will now seek NYSE American approval for a new listing application. Apimeds US, through its subsidiary Lokahi Therapeutics, is focused on developing Apitox, a bee venom-based therapy, for knee osteoarthritis and multiple sclerosis, with plans for a new Phase III trial for OA in the US.
Key Highlights
- Apimeds Pharmaceuticals US, Inc. completed a merger with MindWave Innovations Inc. and Lokahi Therapeutics, Inc. on December 1, 2025.
- MindWave Innovations Inc. became a direct wholly-owned subsidiary of Apimeds US.
- Holders of MindWave common stock will collectively hold 90.9% of Apimeds US's equity on an as-converted and fully diluted basis.
- Shareholders approved a 1-for-10 reverse stock split and a change in par value from $0.01 to $0.001.
- The company approved amendments to the 2024 Equity Incentive Plan and adopted the 2025 Equity Incentive Plan.
- Apimeds US will submit a new listing application to NYSE American due to the change in control.
- Lokahi Therapeutics, a subsidiary, is developing Apitox, a bee venom-based toxin, for knee osteoarthritis (OA) and multiple sclerosis (MS).
- Apitox was previously approved in South Korea for OA, and Apimeds US plans an additional Phase III trial for knee OA in the US.